Abstract Number: 0874 • ACR Convergence 2022
A Tale of Many Canadas: Associations of Ethnicity with Juvenile Idiopathic Arthritis Categories and Disease Severity at Presentation in a Multicultural Universal Healthcare Setting: Results from ReACCh-Out
Background/Purpose: The distribution of Juvenile Idiopathic Arthritis (JIA) categories and disease severity at presentation vary across countries, however it is unclear how much of this…Abstract Number: 2245 • ACR Convergence 2022
Feasibility and Efficacy of a Peer Education Program to Improve Patient Engagement in Lupus Clinical Trials
Background/Purpose: To assess outcomes related to Lupus Therapeutics' Patient Advocates for Lupus Studies (LT-PALS) a peer-to-peer clinical trial (CT) education program designed to improve CT…Abstract Number: 0089 • ACR Convergence 2022
Racial Disparities in Rheumatology Clinical Trials
Background/Purpose: Healthcare disparities exist in patients living with rheumatologic diseases. Factors contributing to disparities include age, sex, race, or sociodemographic variables, each playing a crucial…Abstract Number: 0113 • ACR Convergence 2022
Escalation to Biologics After Methotrexate Among US Veterans with Rheumatoid Arthritis Living in Rural versus Urban Areas
Background/Purpose: Timely diagnosis and initiation of appropriate treatments are imperative to improve outcomes for patients with rheumatoid arthritis (RA). Racial and ethnic disparities in RA…Abstract Number: 0965 • ACR Convergence 2022
Pregnancy Outcomes in a Diverse Lupus Cohort
Background/Purpose: Although the overall systemic lupus (SLE) patient population is racially and ethnically diverse, many study populations are homogeneous. We assembled a diverse group of…Abstract Number: 0352 • ACR Convergence 2021
Native American and African American Rheumatic Disease Patients Exhibit Accelerated Biological Aging Compared to European Americans
Background/Purpose: The universal process of aging is associated with increased risk of disease and death as a result of changing physiologic and molecular processes. In…Abstract Number: 0606 • ACR Convergence 2021
How Might We Care for Rheumatoid Arthritis (RA) Patients Unable to See a Rheumatologist And/or Use Certain of Our Medications? Proposed Preliminary Recommendations for RA Patients Who Don’t Meet Our Established Guidelines
Background/Purpose: Physicians share responsibilities to promote social justice and assure equitable healthcare for all. Street medicine (SM) is a field dedicated to address the need…Abstract Number: 0976 • ACR Convergence 2021
Cumulative Social Disadvantage Predicts an Arthritis Diagnosis: A Cross-sectional Analysis of the National Survey of Children’s Health (NSCH)
Background/Purpose: The impact of social determinants of health in juvenile idiopathic arthritis (JIA) remains poorly understood. Racial disparities exist in JIA, including increased pain and…Abstract Number: 0454 • ACR Convergence 2021
Lupus Nephritis Mortality in the United States, 1999-2019: Profound Disparities by Race/Ethnicity and Place of Residence and a Recent Worsening Trend
Background/Purpose: Mortality from SLE has improved over the last two decades, but remains disproportionately high relative to general population mortality. Lupus nephritis (LN) occurs in…Abstract Number: 0609 • ACR Convergence 2021
Challenges of Caring for Patients with Inflammatory Arthritis Experiencing Homelessness: Preliminary (12- Month) Follow-up Observations and Identification of Certain Barriers to Care
Background/Purpose: Homelessness is a public health crisis. Those with housing insecurity have unique barriers to healthcare that confound their outcomes. Because of the paucity of…Abstract Number: 1056 • ACR Convergence 2021
Characterization of the Patterns of Care, Access and Direct Costs of Systemic Lupus Erythematosus in Brazil: Findings from the Macunaíma Study
Background/Purpose: This study evaluated the patterns of care, access and direct costs related to the management and treatment of patients with systemic lupus erythematosus (SLE)…Abstract Number: 0464 • ACR Convergence 2021
The Impact of Timely Post-Discharge Follow-up on Readmission Risk Among Patients with Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) has the 6th highest hospital readmission rate of all US chronic diseases with significant health disparities and costs. Transitional care…Abstract Number: 0610 • ACR Convergence 2021
Evaluating Patient No Show Rates to Rheumatology Appointments Across a Regional Healthcare System
Background/Purpose: No-show visits in various clinical settings are costly to providers and to health care systems, potentially representing between 3-14% of a clinic’s yearly income.…Abstract Number: 1122 • ACR Convergence 2021
Patient-perceived Solutions to the Treatment Barriers in Knee Osteoarthritis: A Qualitative Study from a Diverse Patient Group Including Racial/ethnic Minorities
Background/Purpose: Knee osteoarthritis (OA) has worse outcomes in racial/ethnic minorities. Yet, most of the qualitative studies include primarily Caucasian people with knee OA, with minimal…Abstract Number: 0492 • ACR Convergence 2021
Racial Differences in Glucocorticoid Use Among Medicaid Beneficiaries with Incident Systemic Lupus Erythematosus
Background/Purpose: Glucocorticoids (GCs) are an integral part of systemic lupus erythematosus (SLE) treatment. Long-term use of GCs is associated with adverse effects. This study evaluated…
- « Previous Page
- 1
- …
- 15
- 16
- 17
- 18
- 19
- …
- 22
- Next Page »
